Article in Science signaling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Vivian ChuaDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0002-1873-6820
Melisa Lopez-AntonDivision of Hematology and Oncology, Department of Medicine, Department of Otolaryngology, Department of Oncological Sciences, Black Family Stem Cell Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA.
Mizue TeraiDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0003-2672-9468
Ryota TanakaDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0002-1562-4049
Usman BaqaiDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.
Timothy J PurwinDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0002-7053-8039
Jelan I HajDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.
Francis J WaltrichDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.
Isabella TrachtenbergDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0009-0003-0341-2828
Kristine LuoDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0002-2894-202X
Rohith TudiDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0009-0007-6032-2959
Angela JeonDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.
Anna HanDepartment of Food Science and Human Nutrition, Jeonbuk National University, Jeonju, Jeollabuk-do 54896, Republic of Korea.ORCID 0000-0001-8180-6214
Inna ChervonevaDivision of Biostatistics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0002-9104-4505
Michael A DaviesDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.ORCID 0000-0002-0977-0912
Julio A Aguirre-GhisoDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461 USA.ORCID 0000-0002-6694-6507
Takami SatoDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0003-2221-0415
Andrew E AplinDepartment of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107 USA.ORCID 0000-0002-2734-3244
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal MelanomaR01CA257505 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI APLIN, ANDREW ERIC, GUTKIND, JORGE SILVIO · 2021 to 2025
$2.7M
Mechanisms of uveal melanoma dormancy and targeted therapy toleranceR01CA253977 · NCI · THOMAS JEFFERSON UNIVERSITY · PI AGUIRRE-GHISO, JULIO A., APLIN, ANDREW ERIC · 2020 to 2024
$2.4M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
Uveal melanoma (UM) is the deadliest form of eye cancer in adults. Inactivating mutations and/or loss of expression of the gene encoding BRCA1-associated protein 1 (BAP1) in UM tumors are associated with an increased risk of metastasis. To investigate the mechanisms underlying this risk, we explored the functional consequences of BAP1 deficiency. UM cell lines expressing mutant
Indexed as
Cell ProliferationMelanomaSignal TransductionTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMutationPhosphorylationRibosomal Protein S6Stress, PhysiologicalUveal MelanomaBAP1 protein, humanRibosomal Protein S6Tumor Suppressor ProteinsUbiquitin Thiolesterase
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. · full record | OpenQuestion